GlaxoSmithKline trumpets a PhIII win in one of Hal Barron's handpicked drugs, a day after FibroGen's faceplant. Will it matter enough to critics?
As GlaxoSmithKline CEO Emma Walmsley charts a new course ahead of the Big Pharma’s planned split while simultaneously under immense pressure from activist investors, the company is touting positive topline results from a late-stage program Friday morning. And it comes less than 24 hours after FibroGen and AstraZeneca ran into a slapdown at an FDA adcomm for a similar drug.
The data come from an experimental drug known as daprodustat, with GSK evaluating the candidate for anemia associated with chronic kidney disease. Daprodustat reached its primary endpoints in five Phase III trials across a variety of patient populations and dosing regimens, GSK announced, ahead of planned regulatory submissions expected in 2022.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.